Systemic sclerosis & Raynaud's
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
Authors' conclusion
Despite the small trial size, a signal emerged suggesting that even in patients with established SSc, C21 may confer benefit for RP
Study context
- Population
- Female patients with SSc and SSc-related RP (median age 58.5 years, median duration of RP 19.0 years)cross-over
- Participants
- 12 patients
- Comparison
- Single oral dose of C21 vs placebo
- Primary endpoint
- AUC for rewarming for each finger (eight fingers) over 15 min after a standard hand cold challenge
- Follow-up
- 15 min
Methodological detailsphase IIa, double-blind, cross-over, single-dose, placebo-controlled, single-centre, Multiplicative ANCOVA models
- Phase IIa
- Double-blind
- Cross-over
- Single-dose
- Placebo-controlled
- Single-centre
- Multiplicative ANCOVA models
Primary result
As reported in the abstract
AUC for rewarming, all eight fingers combined
P = 0.380
Secondary outcomes
Maximum finger temperature after rewarming (MAX) · 15 min
P = 0.036
Original publication
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s. Rheumatology (Oxford). Published 27 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →